4.5 Article

Cerebrospinal Fluid α-Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 43, Issue 3, Pages 1007-1016

Publisher

IOS PRESS
DOI: 10.3233/JAD-141287

Keywords

Alpha-synuclein; Alzheimer's disease; cerebrospinal fluid; cognition; hallucinations; tau

Categories

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. National Institute on Aging
  3. National Institute of Biomedical Imaging and Bioengineering
  4. ADNI clinical sites in Canada
  5. Northern California Institute for Research and Education
  6. Swedish Research Council
  7. Goteborgs Lakaresallskap
  8. Svenska Lakaresallskapet
  9. Sahlgrenska Universitetssjukhuset
  10. Carl-Bertil Laurells fond
  11. Klinisk Biokemi i Norden
  12. Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment
  13. Medical Research Service of the Veterans Affairs Medical Center of San Francisco
  14. Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC)

Ask authors/readers for more resources

Background: Reduced cerebrospinal fluid (CSF) alpha-synuclein has been described in synucleinopathies, including dementia with Lewy bodies (DLB). Common symptoms of DLB include visual hallucinations and visuospatial and executive deficits. Co-occurrence of Lewy body pathology is common in Alzheimer's disease (AD) patients, but it is unknown if reduced CSF alpha-synuclein is associated with Lewy body-like symptomatology in AD. Objective: Determine associations between CSF alpha-synuclein and Lewy body-like symptomatology. Methods: We included 73 controls (NC), 121 mild cognitive impairment (MCI) patients, and 61 AD patients (median follow-up 3.5 years, range 0.6-7.8). We tested associations between baseline CSF alpha-synuclein and visual hallucinations and (longitudinal) cognition. Models were tested with and without co-varying for CSF total tau (T-tau), which is elevated in AD patients, and believed to reflect neurodegeneration. Results: Hallucinations were reported in 20% of AD patients, 13% of MCI patients, and 8% of NC. In AD, low CSF alpha-synuclein was associated with hallucinations. When adjusting for CSF T-tau, low CSF alpha-synuclein was associated with accelerated decline of executive function (NC, MCI, and AD), memory (MCI and AD), and language (MCI). Conclusion: The associations of low CSF alpha-synuclein with hallucinations and poor executive function, which are hallmarks of DLB, indirectly suggest that this biomarker may reflect underlying synuclein pathology. The associations with memory and language in MCI and AD suggests either that reduced CSF alpha-synuclein also partly reflects global impaired neuronal/synaptic function, or that non-specific overall cognitive deterioration is accelerated in the presence of synuclein related pathology. The findings will require autopsy verification.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Psychiatry

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease

Maurits Johansson, Erik Stomrud, Philip S. Insel, Antoine Leuzy, Per Marten Johansson, Ruben Smith, Zahinoor Ismail, Shorena Janelidze, Sebastian Palmqvist, Danielle van Westen, Niklas Mattsson-Carlgren, Oskar Hansson

Summary: The study revealed that in early-stage Alzheimer's disease, mild behavioral impairment is associated with tau pathology independently of memory deficits. This indicates that mild behavioral impairment is an important early clinical manifestation related to tau pathology in Alzheimer's disease.

TRANSLATIONAL PSYCHIATRY (2021)

Article Clinical Neurology

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease

Oskar Hansson, Nicholas Cullen, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren

Summary: The study found that high plasma tau levels were associated with hypometabolism and cortical atrophy, and these associations were observed only in Aβ-positive participants. Plasma phosphorylated tau may help identify and track processes linked to neurodegeneration in Alzheimer's disease.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Article Clinical Neurology

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Shorena Janelidze, David Berron, Ruben Smith, Olof Strandberg, Nicholas K. Proctor, Jeffrey L. Dage, Erik Stomrud, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Oskar Hansson

Summary: This study highlights the potential of plasma P-tau217 as an early biomarker for Alzheimer's disease, showing elevated levels before tau-PET detected insoluble tau aggregates. Modeling suggests that changes in plasma and CSF P-tau217 precede tau-PET signals, indicating its usefulness in detecting early AD brain pathology.

JAMA NEUROLOGY (2021)

Article Clinical Neurology

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory

David Berron, Jacob W. Vogel, Philip S. Insel, Joana B. Pereira, Long Xie, Laura E. M. Wisse, Paul A. Yushkevich, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Erik Stomrud, Ruben Smith, Olof Strandberg, Oskar Hansson

Summary: The study reveals the progression of tau pathology across subregions within the medial temporal lobe and its specific association with memory performance at different disease stages. In cognitively unimpaired individuals, increased tau load is linked to local atrophy and memory performance, while in mild cognitive impairment patients, the association between hippocampal tau load and memory performance is partially mediated by posterior hippocampal atrophy.

BRAIN (2021)

Review Medicine, Research & Experimental

Blood-based biomarkers for Alzheimer's disease

Antoine Leuzy, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Shorena Janelidze, Jeffrey L. Dage, Oskar Hansson

Summary: Blood-based biomarkers are playing an increasing role in the diagnosis and research of neurodegenerative disorders like Alzheimer's disease. Biomarkers such as plasma P-tau and NfL show promising potential for detection and monitoring of these diseases.

EMBO MOLECULAR MEDICINE (2022)

Article Neurosciences

Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest

Erik Blennow Nordstrom, Gisela Lilja, Susann Ullen, Kaj Blennow, Hans Friberg, Christian Hassager, Jesper Kjaergaard, Niklas Mattsson-Carlgren, Marion Moseby-Knappe, Niklas Nielsen, Susanna Vestberg, Henrik Zetterberg, Tobias Cronberg

Summary: This study explored the associations between different methods of assessing long-term neurocognitive outcome after out-of-hospital cardiac arrest and early hypoxic-ischemic brain injury assessed by a biomarker. The results showed that serum neurofilament light (NFL) was associated with all outcome instruments, but the association with patient-reported measures was weaker. The clinician-reported Cerebral Performance Category (CPC) was mostly related to hypoxic-ischemic brain injury, but had a ceiling effect.

BRAIN INJURY (2022)

Article Clinical Neurology

β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease

Atul Kumar, Shorena Janelidze, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson, Niklas Mattsson-Carlgren

Summary: This study investigated the associations between genetic risk factors for Alzheimer's disease (AD) and biomarkers in cerebrospinal fluid (CSF). The results showed that the genetic risk scores were associated with higher levels of soluble phosphorylated tau, and these associations were partly mediated by beta-amyloid pathology. The study identified Aβ-dependent and Aβ-independent subsets of the genetic risk scores. The findings have implications for the development of anti-tau drugs.

NEUROLOGY (2022)

Article Clinical Neurology

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals

Colin Groot, Ruben Smith, Erik Stomrud, Alexa Pichet Binette, Antoine Leuzy, Anika Wuestefeld, Laura E. M. Wisse, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Shorena Janelidze, Olof Strandberg, Rik Ossenkoppele, Oskar Hansson

Summary: Among amyloid-positive individuals, tau discordance predicts increased rates of tau accumulation on PET, but not increased cognitive decline or cortical thinning. Individuals with this biomarker profile may be an interesting target group for intervention in early Alzheimer's disease.

BRAIN (2023)

Editorial Material Clinical Neurology

The emerging era of staging Alzheimer's disease pathology using plasma biomarkers

Niklas Mattsson-Carlgren, Sebastian Palmqvist

BRAIN (2023)

Article Medicine, Research & Experimental

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Gemma Salvado, Rik Ossenkoppele, Nicholas J. Ashton, Thomas G. Beach, Geidy E. Serrano, Eric M. Reiman, Henrik Zetterberg, Niklas Mattsson-Carlgren, Shorena Janelidze, Kaj Blennow, Oskar Hansson

Summary: Several promising plasma biomarkers for Alzheimer's disease have been developed, but their neuropathological correlates are not fully understood. This study investigates the associations between multiple plasma biomarkers and amyloid and tau neuropathological measures. The results suggest that plasma p-tau217 and A beta 42/40 might be an optimal combination for assessing Alzheimer's-related pathology.

EMBO MOLECULAR MEDICINE (2023)

Article Clinical Neurology

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia

Eske Christiane Gertje, Shorena Janelidze, Danielle van Westen, Nicholas Cullen, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson, Niklas Mattsson-Carlgren

Summary: There is an association between white matter lesions (WML) and CSF biomarkers of neuroinflammation in individuals without dementia. Especially, PlGF is associated with WML independent of Aβ status and cognitive impairment.

NEUROLOGY (2023)

Article Clinical Neurology

Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort study

Elin Dybjer, Atul Kumar, Katarina Nagga, Gunnar Engstrom, Niklas Mattsson-Carlgren, Peter M. Nilsson, Olle Melander, Oskar Hansson

Summary: Dybjer et al. found that the polygenic risk of type 2 diabetes is associated with the risk of dementia, especially vascular dementia. However, further analysis did not support a causal relationship between type 2 diabetes and vascular dementia. It is still unclear whether the genetic risk markers for type 2 diabetes and dementia are the same or if there is a causal link between the two diseases.

BRAIN COMMUNICATIONS (2023)

Article Clinical Neurology

Plasma phosphorylated tau 217 in preclinical Alzheimer's disease

Erin M. Jonaitis, Shorena Janelidze, Karly A. Cody, Rebecca Langhough, Lianlian Du, Nathaniel A. Chin, Niklas Mattsson-Carlgren, Kirk J. Hogan, Bradley T. Christian, Tobey J. Betthauser, Oskar Hansson, Sterling C. Johnson

Summary: An accurate blood test for early detection of Alzheimer's disease is important for secondary prevention. In this study, plasma phosphorylated tau 217 (pTau(217)) was found to be strongly related to amyloid and tau PET markers, and could predict longitudinal cognitive performance.

BRAIN COMMUNICATIONS (2023)

Article Cell Biology

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology

Joana B. Pereira, Shorena Janelidze, Olof Strandberg, Christopher D. Whelan, Henrik Zetterberg, Kaj Blennow, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansson

Summary: The study investigates the role of microglia in tau accumulation and cognitive decline, and identifies several cell markers associated with these processes. These findings have implications for the development of future therapeutic strategies for Alzheimer's disease.

NATURE AGING (2022)

Article Clinical Neurology

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ε4 carriers

Nicola Spotorno, Chloe Najac, Erik Stomrud, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Danielle van Westen, Itamar Ronen, Oskar Hansson

Summary: This study provides further evidence of the important role of astrocytes in the pathophysiology of Alzheimer's disease and investigates the relationship between APOE genotype, myo-inositol concentration, and Alzheimer's disease pathology. The results show an interaction between myo-inositol concentration and amyloid-beta deposition in APOE ε4 carriers.

BRAIN COMMUNICATIONS (2022)

No Data Available